治疗偏头痛的新型合成药物

这本书发表在《头痛》系列中，得到了欧洲头痛联合会的认可，是第一本关于用地坦类药物（拉米丹）和gepants类药物（阿托格潘、优步健、瑞美潘、vazegepant）对偏头痛进行新型综合治疗的书。这些药物将为偏头痛患者提供额外的选择，这些患者可能会因其他药物而出现副作用，或者对以前的药物反应不理想。现在已经出版了足够多的文献，以引起广泛的多学科读者（普通内科医生、普通神经科医生、临床心理学家、培训中的神经科医生和医学生）的兴趣，他们在临床实践中每天都面临着这种沉重的疾病。因此，本书旨在概述这些用于偏头痛急性和预防性治疗的新药，包括临床证据、耐受性和临床发展的不同阶段的研究。
Novel Synthetic Drugs in Migraine
Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.

OR